

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and  
Waiver under 18 U.S.C. §208(b)(3)

Michael McClung, M.D.

**Committees:** Endocrinologic & Metabolic Drugs  
Advisory Committee and the  
Advisory Committee for  
Pharmaceutical Science Meeting

**Meeting Date:** October 4, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the joint committees' discussions of FDA's efforts to assess the product quality of currently marketed levothroxine sodium drug products. Earlier this year, FDA requested that manufacturers of currently marketed levothroxine sodium products provide to it certain product release and stability information. The joint committee will consider FDA's analyses and any clinical significance. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Advisory Board	Affected Firm	Less than \$10,001per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature of SGE

\_\_\_\_\_/8/29/06\_\_\_\_\_  
Date